Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers

Addiction Biology

Volumn 18, Issue 2, 2013, Pages 332-343

  Walsh, Sharon L ^a   Heilig, Markus ^b   Nuzzo, Paul A ^a   Henderson, Pam ^a   Lofwall, Michelle R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Abuse liability; aprepitant; NK1 antagonist; opioid; oxycodone; substance P

Indexed keywords

APREPITANT; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; OXYCODONE; ANTIEMETIC AGENT; MORPHOLINE DERIVATIVE; NARCOTIC ANALGESIC AGENT; PLACEBO; SUBSTANCE P;

ADULT; ANOREXIA; ARTICLE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG CAPSULE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EUPHORIA; FEMALE; FEVER; HEADACHE; HICCUP; HUMAN; MALE; MIOSIS; NARCOTIC DEPENDENCE; NAUSEA; OPIATE ADDICTION; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; RESPIRATORY FUNCTION; SINGLE DRUG DOSE; TABLET; TASK PERFORMANCE; VISUAL ANALOG SCALE; WEAKNESS; ANALYSIS OF VARIANCE; ANIMAL; AREA UNDER THE CURVE; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG INTERACTION; DRUG TOLERANCE; INTRANASAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; METABOLISM; MOUSE; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOMOTOR PERFORMANCE; REINFORCEMENT; TIME;

ADMINISTRATION, INTRANASAL; ADULT; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANIMALS; ANTIEMETICS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MORPHOLINES; OPIOID-RELATED DISORDERS; OXYCODONE; PLACEBOS; PSYCHOMOTOR PERFORMANCE; RECEPTORS, NEUROKININ-1; REINFORCEMENT (PSYCHOLOGY); SUBSTANCE P; TIME FACTORS;

EID: 84874417013     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2011.00419.x     Document Type: Article

References (51)

1. Aicher SA, Punnoose A, Goldberg A, (2000) mu-Opioid receptors often colocalize with the substance P receptor (NK1) in the trigeminal dorsal horn. J Neurosci 20: 4345-4354. (Pubitemid 30365705)
2. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J, (1961) An inventory for measuring depression. Arch Gen Psychiatry 54: 561-571.
3. Birklein F, Schmelz M, (2008) Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS). Neurosci Lett 437: 199-2002.
4. Costa PT, McCrae RR, (1985) The NEO Personality Inventory Manual. Odessa, FL: Psychological Assessment Resources.
5. Dando TM, Perry CM, (2004) Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64: 777-794. (Pubitemid 38471378)
6. De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJH, Laird JMA, Belmonte C, Cervero F, Hunt SP, (1998) Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 405: 180-183.
7. Derogatis LR, (1983) SCL-90-R. Administration, Scoring and Procedures Manual II, 2nd edn. Baltimore, MD: Clinical Psychometric Research.
8. Ebner K, Singewald N, (2006) The role of substance P in stress and anxiety responses. Amino Acids 31: 251-272. (Pubitemid 44537051)
9. Foran SE, Carr DB, Lipkowski AW, Maszczynska I, Marchand JE, Misicka A, Beinborn M, Kopin AS, Kream RM, (2000) A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic. Proc Natl Acad Sci U S A 97: 7621-7626. (Pubitemid 30431513)
10. Fraser HF, Van Horn GG, Martin WR, Wolbach AB, Isbell H, (1961) Methods for evaluating addiction liability. (A) 'Attitude' of opiate addicts toward opiate-like drugs, (B) A short-term 'direct' addiction test. J Pharmacol Exp Ther 133: 371-378.
11. Gadd CA, Murtra P, De Felipe C, Hunt SP, (2003) Neurokinin-1 receptor-expressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse. J Neurosci 23: 8271-8280. (Pubitemid 37129644)
12. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M, (2008) Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319: 1536-1539. (Pubitemid 351398184)
13. Hargreaves R, (2002) Imaging substance P receptors (NK1) in the living brain using positron emission tomography. J Clin Psychiatry 63: 18-24. (Pubitemid 35435004)
14. Hasenohrl RU, Gerhardt P, Huston JP, (1991) Naloxone blocks conditioned place preference induced by substance P and [pGlu6]-SP(6-11). Regul Pept 35: 177-187.
15. Hasenohrl RU, Gerhardt P, Huston JP, (1992) Positively reinforcing effects of the neurokinin substance P in the basal forebrain: mediation by its C-terminal sequence. Exp Neurol 115: 282-291.
16. Heiskanen T, Olkkola KT, Kalso E, (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64: 603-611. (Pubitemid 29011380)
17. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML, (2005) Pharmacotherapy for nicotine dependence. CA Cancer J Clin 55: 281-299, quiz 322-283, 325. (Pubitemid 41377333)
18. Herin DV, Rush CR, Grabowski J, (2010) Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Ann N Y Acad Sci 1187: 76-100.
19. Herpfer I, Lieb K, (2005) Substance P receptor antagonists in psychiatry. CNS Drugs 19: 275-293.
20. Hill R, (2002) Substance P, opioid and catecholamine systems in the mouse central nervous system (CNS). Proc Natl Acad Sci U S A 99: 549-551. (Pubitemid 34106546)
21. Huang S-C, Korlipara VL, (2010) Neurokinin-1 receptor antagonists: a comprehensive patent survey. Expert Opin Ther Pat 20: 1019-1045.
22. Johanson C-E, Fischman MW, (1989) The pharmacology of cocaine related to its abuse. Pharmacol Rev 41: 3-52. (Pubitemid 19247826)
23. King T, Ossipov MH, Vanderah TW, Porreca F, Lai J, (2005) Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals 14: 194-205. (Pubitemid 41417108)
24. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramke JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves R, Rupniak NMJ, (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 11: 1640-1645. (Pubitemid 28435572)
25. Lofwall MR, Moody DE, Fang WB, Nuzzo PA, Walsh SL, (2011) Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers. J Clin Pharmacol doi:10.1177/ 0091270011401620.x. Epub ahead of print (PMID: 21610203).
26. Lofwall MR, Nuzzo PA, Walsh SL, (in press) Effects of cold pressor pain on the abuse liability of Intranasal Oxycontin® in male and femail opioid abusers. Drug Alcohol Depen.
27. Mai JK, Stephens PH, Hopf A, Cuello AC, (1986) Substance P in the human brain. Neuroscience 17: 709-739. (Pubitemid 16131267)
28. Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL, Crumley TM, Panebianco D, Bradstreet TE, Bergman AJ, Waldman SA, Greenberg HE, Butler K, Knops A, De Lepeleire I, Michiels N, Petty KJ, (2006) Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 46: 291-300. (Pubitemid 43260316)
29. Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, Goldberg MR, Murphy G, Gottesdiener KM, Lines CR, Petty KJ, Blum RA, (2003) Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 74: 150-156. (Pubitemid 36951812)
30. Maldonado R, Girdlestone D, Roques BP, (1993) RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats. Neurosci Lett 156: 135-140. (Pubitemid 23214742)
31. Martin WR, Sloan JW, Sapira JD, Jasinski DR, (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12: 245-258.
32. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grisson G, Pettinati H, Argeriou M, (1992) The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 9: 199-213.
33. McLeod D, Griffiths RR, Bigelow GE, Yingling J, (1982) An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum 14: 463-466.
34. Murtra P, Sheasby AM, Hunt SP, De Felipe C, (2000) Rewarding effects opiates are absent in mice lacking the receptor for substance P. Nature 405: 180-183. (Pubitemid 30313535)
35. Nakade S, Ohno T, Kitagawa J, Hashimoto Y, Katayama M, Awata H, Kodama Y, Miyata Y, (2008) Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol 63: 75-83.
36. Nomura H, Shiosaka S, Tohyama M, (1987) Distribution of substance P-like immunoreactive structures in the brainstem of the adult human brain: an immunocytochemical study. Brain Res 404: 365-370. (Pubitemid 17021921)
37. Pfeiffer M, Kirscht S, Stumm R, Koch T, Wu D, Laugsch M, Schroder H, Hollt V, Schulz S, (2003) Heterodimerization of Substance P and u-opioid receptors regulates receptor trafficking and resensitization. J Biol Chem 278: 51630-51637. (Pubitemid 38020408)
38. Pierce KL, Premont RT, Lefkowitz RJ, (2002) Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3: 639-650. (Pubitemid 34987785)
39. Poyhia R, Seppala T, Olkkola KT, Kalso E, (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33: 617-621.
40. Preston KL, Bigelow GE, Liebson IA, (1987) Comparative evaluation of morphine, pentacozine and ciramadol in postaddicts. J Pharmacol Exp Ther 240: 900-910. (Pubitemid 17043592)
41. Ripley TL, Gadd CA, De Felipe C, Hunt SP, Stephens DN, (2002) Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors. Neuropharmacology 43: 1258-1268. (Pubitemid 36084436)
42. Rubenstein EB, Slusher BS, Rojas C, Navari RM, (2006) New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J 12: 341-347. (Pubitemid 44564817)
43. Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH, Evans DC, Huskey SE, (2004) Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 32: 1287-1292. (Pubitemid 39410914)
44. Santarelli L, Gobbi G, Blier P, Hen R, (2002) Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1). J Clin Psychiatry 63: 11-17. (Pubitemid 35435003)
45. Schuster CR, Johanson C-E, (1981) An analysis of drug-seeking behavior in animals. Neurosci Biobehav Rev 5: 315-323. (Pubitemid 12235557)
46. Strain EC, Stitzer ML, (2006) The Treatment of Opioid Dependence. Baltimore, MD: The Johns Hopkins University Press.
47. Trang T, Quirion R, Jhamandas K, (2005) The spinal basis of opioid tolerance and physical dependence: involvement of calcitonin gene-related peptide, substance P, and arachidonic acid-derived metabolites. Peptides 26: 1346-1355. (Pubitemid 41021469)
48. von Euler US, Gaddum JH, (1931) An unidentified depressor substance in certain tissue extracts. J Physiol 72: 74-87.
49. Waldhoer M, Bartlett SE, Whistler JL, (2004) Opioid receptors. Annu Rev Biochem 73: 953-990. (Pubitemid 39050391)
50. Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr, (2008) The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend 98: 191-202.
51. Yu YJ, Arttamangkul S, Evans CJ, WIlliams JT, von Zastrow M, (2009) Neurokinin 1 receptors regulate morphine-induced endocytosis and densitization of μ-opioid receptors in CNS neurons. J Neurosci 29: 222-233.